Biobot Analytics is the pioneer in wastewater epidemiology, transforming wastewater infrastructure into a real-time observatory for infectious disease activity. Through a national network of wastewater sampling sites and advanced molecular analysis, Biobot detects circulating pathogens earlier than clinical data and provides real-time insights with county- and zip-code level resolution. For pharmaceutical and vaccine manufacturers, Biobot's predictive disease intelligence provides a powerful new layer of real-world evidence to forecast outbreaks, optimize clinical trial site selection and enrollment, and target commercial or vaccination strategies with greater precision.
A spinoff from MIT, Biobot is backed by top venture capital investors and has built wastewater epidemiology platforms for U.S. federal agencies — including the NIH, HHS, CDC, the U.S. military, and ONDCP. Biobot is headquartered in Cambridge, MA.